An overview on dosage forms and formulation strategies for vaccines and antibodies oral delivery

References

• Abdul Fattah AM, Truong-Le V, Yee L, Pan E, Ao Y, Kalonia DS, Pikal MJ. 2007. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability II: stability of a vaccine. Pharm Res. 24:715–727.
   PubMed Web of Science ®Google Scholar
• Abdul-Fattah AM, Truong-Le V, Yee L, Nguyen L, Kalonia DS, Cicerone MT, Pikal MJ. 2007. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody. J Pharm Sci. 96(8):1983–2008.
   PubMed Web of Science ®Google Scholar
• Adams GD. 2003. Lyophilization of vaccines: current trends. Methods Mol Med. 87:223–244.
   PubMedGoogle Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. 2013. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 8(1):102.
   PubMed Web of Science ®Google Scholar
• Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS Pharm Sci. 5(2):21–31.
   Google Scholar
• Anish C, Upadhyay AK, Sehgal D, Panda AK. 2014. Influences of process and formulation parameters on powder flow properties and immunogenicity of spray dried polymer particles entrapping recombinant pneumococcal surface protein A. Int J Pharm. 466(1–2):198–210.
   PubMedGoogle Scholar
• Año G, Esquisabel A, Pastor M, Talavera A, Cedré B, Fernández S, Sifontes S, Aranguren Y, Falero G, García L, et al. 2011. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae. Vaccine. 29(34):5758–5764.
   PubMed Web of Science ®Google Scholar
• Aschenbrenner M, Grammueller E, Kulozik U, Foerst P. 2014. The contribution of the inherent restricted mobility of glassy sugar matrices to the overall stability of freeze-dried bacteria determined by low-resolution solid-state 1H-NMR. Food Bioprocess Technol. 7(4):1012–1024.
   Web of Science ®Google Scholar
• Bakke H, Samdal H, Holst J, Oftung F, Haugen IL, Kristoffersen AC, Haugan A, Janakova L, Korsvold GE, Krogh G. 2006. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Immunol. 63(3):223–231.
   PubMed Web of Science ®Google Scholar
• Barnes GL, Hewson PH, Mclellan JA, Doyle LW, Knoches AML, Kitchen WH. 1982. A randomized trial of oral gammaglobulin in low-birth-weight infants infected with rotavirus. Lancet J. 319(8286):1371–1373.
   Google Scholar
• Bhol KC, Tracey DE, Lemos BR, Lyng GD, Erlich EC, Keane DM, Quesenberry MS, Holdorf AD, Schlehuber LD, Clark SA, et al. 2013. AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis. 19(11):2273–2281.
   PubMed Web of Science ®Google Scholar
• Biswas S, Chattopadhyay M, Sen KK, Saha MK. 2015. Development and characterization of alginate coated low molecular weight chitosan nanoparticles as new carriers for oral vaccine delivery in mice. Carbohydr Polym. 121:403–410.
   PubMed Web of Science ®Google Scholar
• Blum PM, Phelps DL, Ank BJ, Krantman HJ, Richard SE. 1981. Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants. Pediatr Res. 15(9):1256–1260.
   PubMed Web of Science ®Google Scholar
• Bogstedt AK, Nord CE, Hammarström L. 1995. Lack of effect of orally administered human serum immunoglobulin on the normal human oral and intestinal microflora. Eur J Clin Microbiol Infect Dis. 14(1):61–64.
   PubMed Web of Science ®Google Scholar
• Borde A, Ekman A, Holmgren J, Larsson A. 2012. Effect of protein release rates from tablet formulations on the immune response after sublingual immunization. Eur J Pharm Sci. 47(4):695–700.
   PubMed Web of Science ®Google Scholar
• Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. 2007. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur J Pharm Sci. 32(4–5):278–290.
   PubMed Web of Science ®Google Scholar
• Bowman K, Leong KW. 2006. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomed. 1(2):117–128.
   PubMed Web of Science ®Google Scholar
• Brannon-Peppas L. 1995. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm. 116(1):1–9.
   Web of Science ®Google Scholar
• Busignies V, Simon G, Mollereau G, Bourry O, Mazel V, Rosa-Calatrava M, Tchoreloff P. 2018. Development and pre-clinical evaluation in the swine model of a mucosal vaccine tablet for human influenza viruses: a proof-of-concept study. Int J Pharma. 538(1–2):87–96.
   PubMed Web of Science ®Google Scholar
• Caon T, Jin L, Simões CMO, Norton RS, Nicolazzo JA. 2015. Enhancing the buccal mucosal delivery of peptide and protein therapeutics. 2015. Pharm Res. 32(1):1–21.
   PubMed Web of Science ®Google Scholar
• Caparino OA, Tang J, Nindo CI, Sablani SS, Powers JR, Fellman JK. 2012. Effect of drying methods on thephysical properties and microstructures of mango powder. J Food Eng. 111(1):135–148.
   Web of Science ®Google Scholar
• Carpenter JF, Crowe JH. 1989. An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry. 28(9):3916–3922.
   PubMed Web of Science ®Google Scholar
• Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. 2002. Rational design of stable lyophilized protein formulations: theory and practice. Pharm Biotechnol. 13:109–133.
   PubMedGoogle Scholar
• Carreño JM, Perez-Shibayama C, Gil-Cruz C, Printz A, Pastelin R, Isibasi A, Chariatte D, Tanoue Y, Lopez-Macias C, Gander B. 2016. PLGA-microencapsulation protects Salmonella typhi outer membrane proteins from acidic degradation and increases their mucosal immunogenicity. Vaccine. 34(35):4263–4269.
   PubMed Web of Science ®Google Scholar
• Chang LL, Shepherd D, Sun J, Tang XC, Pikal MJ. 2005. Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: implications for the mechanism of protein stabilization in the solid state. J Pharm Sci. 94(7):1445–1455.
   PubMed Web of Science ®Google Scholar
• Chen DJ. 2012. Formulation of HPV dry powder wafers for sublingual vaccination. CU scholar. [undergraduate honors theses]. 278. Boulder (CO): University of Colorado Boulder.
   Google Scholar
• Chesko J, Fox C, Dutill T, Vedvick T, Reed S. 2011. Lyophilization and stabilization of vaccines. In Singh M, Srivastava IK, editors. Development of vaccines: from discovery to clinical testing. Hoboken (NJ): John Wiley & Sons; p. 385–397.
   Google Scholar
• Choonara BF, Choonara YE, Kumar P, Bijukumar D, Du Toit LC, Pillay V. 2014. A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv. 32(7):1269–1282.
   PubMed Web of Science ®Google Scholar
• Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, Brooks D, Hsu C, Carpenter JF. 2001. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci. 90(3):310–321.
   PubMed Web of Science ®Google Scholar
• Clemens J, Shin S, Sur D, Nair GB, Holmgren J. 2011. New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol. 8(12):701–710.
   PubMed Web of Science ®Google Scholar
• Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR. 1988. Crossprotection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis. 158(2):372–377.
   PubMed Web of Science ®Google Scholar
• Conacher M, Alexander J, Brewer JM. 2001. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 19(20–22):2965–2974.
   PubMed Web of Science ®Google Scholar
• Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. 2012. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J. 103(1):69–78.
   PubMed Web of Science ®Google Scholar
• Davitt CJH, Lavelle EC. 2015. Delivery strategies to enhance oral vaccination against enteric infections. 2015. Adv Drug Deliv Rev. 91:52–69.
   PubMed Web of Science ®Google Scholar
• Demento SL, Cui W, Criscione JM, Stern E, Tulipan J, Kaech SM, Fahmy TM. 2012. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 33(19):4957–4964.
   PubMed Web of Science ®Google Scholar
• Duddu SP, Dal Monte PR. 1997. Effect of glass transition temperature on the stability of lyophilized formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res. 14(5):591–595.
   PubMed Web of Science ®Google Scholar
• Duddu SP, Zhang G, Dal Monte PR. 1997. The relationship between protein aggregation and molecular mobility below the glass transition temperature of lyophilized formulations containing a monoclonal antibody. Pharm Res. 14(5):596–600.
   PubMed Web of Science ®Google Scholar
• Durán-Lobato M, Carrillo-Conde B, Khairandish Y, Peppas NA. 2014. Surface-modified P(HEMA-co-MAA) nanogel carriers for oral vaccine delivery: design, characterization, and in vitro targeting evaluation. Biomacromolecules. 15(7):2725–2734.
   PubMed Web of Science ®Google Scholar
• Ensign LM, Cone R, Hanes J. 2012. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 64(6):557–570.
   PubMed Web of Science ®Google Scholar
• Epstein MS, Ehrenpreis ED, Kulkarni PM. 2014. Biosimilars: the need, the challenge, the future: the FDA perspective. Am J Gastroenterol. 109(12):1856–1859.
   PubMed Web of Science ®Google Scholar
• Faghihi H, Merrikhihaghi S, Najafabadi AR, Ramezani V, Sardari S, Vatanara A. 2016. A comparative study to evaluate the effect of different carbohydrates on the stability of immunoglobulin G during lyophilization and following storage. Pharm Sci. 22(4):251–259.
   Google Scholar
• Fernandez S, Anõ G, Castanõ J, Pino Y, Uribarri E, Riveron LA, Cedré B, Valmaseda T, Falero G, Pérez JL. 2013. Evaluation of enteric-coated tablets as a whole cell inactivated vaccine candidate against Vibrio cholera. Trav Med Inf Dis. 11:103–109.
   PubMed Web of Science ®Google Scholar
• Fraser A, Paul M, Goldberg E, Acosta CJ, Leibovici L. 2007. Typhoidfever vaccines: systematic review and meta-analysis ofrandomised controlled trials. Vaccine. 25(45):7848–7857.
   PubMed Web of Science ®Google Scholar
• Fu K, Pack DW, Klibanov AM, Langer R. 2000. Visual evidence of acidic environment within degrading poly (lactic-co-glycolic acid) (PLGA) microspheres. Pharm Res. 17(1):100–106.
   PubMed Web of Science ®Google Scholar
• Genina N, Fors D, Palo M, Peltonen J, Sandler N. 2013. Behavior of printable formulations of loperamide and caffeine on different substrates—effect of print density in inkjet printing. Int J Pharm. 453(2):488–497.
   PubMed Web of Science ®Google Scholar
• Grasmeijer N, Stankovic M, de Waard H, Frijlink HW, Hinrichs WL. 2013. Unraveling protein stabilization mechanisms: Vitrification and water replacement in a glass transition temperature controlled system. Biochim Biophys Acta. 1834(4):763–769.
   PubMed Web of Science ®Google Scholar
• Hageman MJ. 1988. The role of moisture in protein stability. Drug Dev Ind Pharm. 14:2047–2070.
   Web of Science ®Google Scholar
• Harde H, Agrawal AK, Jain S. 2014. Development of stabilized glucomannosylated chitosan nanoparticles using tandem crosslinking method for oral vaccine delivery. Nanomedicine. 9(16):2511–2559.
   PubMed Web of Science ®Google Scholar
• Harris MS, Hartman D, Lemos BR, Erlich EC, Spence S, Kennedy S, Ptak T, Pruitt R, Vermeire S, Fox BS. 2016. AVX-470, an orally delivered anti-tumour necrosis factor antibody for treatment of active ulcerative colitis: results of a first-in-human trial. J Crohns Colitis. 10(6):631–640.
   PubMed Web of Science ®Google Scholar
• Hartman DS, Tracey DE, Lemos BR, Erlich EC, Burton RE, Keane DM, Patel R, Kim S, Bhol KC, Harris MS, et al. 2016. Effects of AVX-470, an oral, locally acting anti-tumour necrosis factor antibody, on tissue biomarkers in patients with active ulcerative colitis. J Crohns Colitis. 10(6):641–649.
   PubMed Web of Science ®Google Scholar
• Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. 2014. Clinical development success rates for investigational drugs. Nat Biotechnol. 32(1):40–51.
   PubMed Web of Science ®Google Scholar
• He XW, Wang F, Jiang I, Li J, Liu SK, Xiao ZY, Jin XQ, Zhang YN, He Y, Li K. 2005. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J Gen Virol. 86(3):601–610.
   PubMed Web of Science ®Google Scholar
• Hilpert H, Briissow H, Mietens C, Sidoti J, Lerner L, Werchau H. 1987. Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis. 156(1):158–166.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Svennerholm AM. 2012. Vaccines against mucosal infections. Curr Opin Immunol. 24(3):343–353.
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat Med. 11(S4):S45–S53.
   PubMed Web of Science ®Google Scholar
• Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, Lewis D. 2012. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLoS One. 7(3):e33736–8.
   PubMed Web of Science ®Google Scholar
• Hwang SR, Byun Y. 2014. Advances in oral macromolecular drug delivery. Expert Opin Drug Deliv. 11(12):1955–1967.
   PubMed Web of Science ®Google Scholar
• Ibraheem D, Elaissari A, Fessi H. 2014. Administration strategies for proteins and peptides. Int J Pharm. 477(1–2):578–589.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. 2007. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 56(8):2103–2109.
   PubMed Web of Science ®Google Scholar
• Iyengar L, Selvaraj RJ. 1972. Intestinal absorption of immunoglobulins by newborn infants. Arch Dis Child. 47(253):411–414.
   PubMed Web of Science ®Google Scholar
• Iyire A, Alaayedi M, Mohammed AR. 2016. Pre-formulation and systematic evaluation of amino acid assisted permeability of insulin across in vitro buccal cell layers. Scientific Rep. 6:32498.
   PubMed Web of Science ®Google Scholar
• Jain S, Sharma RK, Vyas SP. 2006. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. J Pharm Pharmacol. 58(3):303–310.
   PubMed Web of Science ®Google Scholar
• Jayasundera M, Adhikari B, Adhikari R, Aldred P. 2011. The effects of proteins and low molecular weight surfactants on spray drying of model sugar-rich foods: powder production and characterisation. J Food Eng. 104(2):259–271.
   Web of Science ®Google Scholar
• Joslin E, Gray H, Root HF. 1992. Insulin in hospital and home. J Metab Res. 2:651–699.
   Google Scholar
• Jovanovic N, Bouchard A, Hofland GW, Witkamp GJ, Crommelin DJ, Jiskoot W. 2008. Stabilization of IgG by supercritical fluid drying: optimization of formulation and process parameters. Eur J Pharm Biopharm. 68:183–190.
   PubMed Web of Science ®Google Scholar
• Kanojia G, Have RT, Bakker A, Wagner K, Frijlink HW, Kersten GF, Amorij JP. 2016. The production of a stable infliximab powder: the evaluation of spray and freeze-drying for production. PLoS One. 11:0163109.
   Web of Science ®Google Scholar
• Kanojia G, Willems GJ, Frijlink HW, Kersten GF, Soema PC, Amorij JP. 2016. A design of experiment approach to predict product and process parameters for a spray dried influenza vaccine. Int J Pharm. 511(2):1098–1111.
   PubMedGoogle Scholar
• Khan TA, Mahler HC, Kishore RS. 2015. Key interactions of surfactants in therapeutic protein formulations: a review. Eur J Pharm Biopharm. 97:60–67.
   PubMed Web of Science ®Google Scholar
• Kim L, Martinez CJ, Hodgson KA, Trager GR, Brandl JR, Sandefer EP, Doll WJ, Liebowitz D, Tucker SN. 2016. Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule. Scientific Rep. 6:37295.
   PubMed Web of Science ®Google Scholar
• Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP. 2014. Buccal and sublingual vaccine delivery. J Control Release. 190:580–592.
   PubMed Web of Science ®Google Scholar
• Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB. 2014. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 42(5):237–259.
   PubMed Web of Science ®Google Scholar
• Kunisawa J, Kurashima Y, Kiyono H. 2012. Gut-associated lymphoid tissues for the development of oral vaccines. Adv Drug Deliv Rev. 64(6):523–530.
   PubMed Web of Science ®Google Scholar
• Laffleur F, Wagner J, Barthelmes J. 2015. A potential tailor-made hyaluronic acid buccal delivery system comprising rotigotine for Parkinson’s disease? Future Med Chem. 7(10):1225–1232.
   PubMed Web of Science ®Google Scholar
• Laffleur F. 2014. Mucoadhesive polymers for buccal drug delivery. Drug Dev Ind Pharm. 40(5):591–598.
   PubMed Web of Science ®Google Scholar
• Laffleur F, Leder N, Barthelmes J. 2016. In vitro evaluation of thio-poly acrylic acid for intraoral delivery. Drug Deliv. 23(6):2065–2073.
   PubMed Web of Science ®Google Scholar
• Lal M, Priddy S, Bourgeois L, Walker R, Pebley W, Brown J, Desai J, Darsley MJ, Kristensen D, Chen D. 2013. Development of a fast-dissolving tablet formulation of a live attenuated enterotoxigenic E. coli vaccine candidate. Vaccine. 31(42):4759–4764.
   PubMed Web of Science ®Google Scholar
• Lal M, White J, Zhu C. 2017. Preparing an adjuvanted thermoresponsive gel formulation for sublingual vaccination. In: Fox C, editor. Vaccine adjuvants, methods in molecular biology. New York (NY): Humana Press; p. 153–163.
   Google Scholar
• Langford A, Bhatnagar B, Walters R, Tchessalov S, Ohtake S. 2018. Drying of biopharmaceuticals: recent developments, new technologies and future direction. Jpn J Food Eng. 19(1):15–24.
   Google Scholar
• Lee SH, Heng D, Ng WK, Chan HK, Tan RB. 2011. Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. Int J Pharm. 403(1–2):192–200.
   PubMed Web of Science ®Google Scholar
• Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. 1999. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine. 17(2):S22–S27.
   PubMedGoogle Scholar
• Liau JJ, Hook S, Prestidge CA, Barnes TJ. 2015. A lipid based multi-compartmental system: liposomes-in-double emulsion for oral vaccine delivery. Eur J Pharm Biopharm. 97A:15–21.
   Google Scholar
• Lin W, McEntee N, Farrell C, Scholes P. 1997. Delivery of antibodies to the gastrointestinal tract for local actions. Nottingham: Quotient Clinical.
   Google Scholar
• Liu J, Nguyen MD, Andya JD, Shire SJ. 2005. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci. 94(9):1928–1940.
   PubMed Web of Science ®Google Scholar
• Losonsky GA, Johnson JP, Winkelstein JA, Yolken RH. 1985. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest. 76(6):2362–2367.
   PubMed Web of Science ®Google Scholar
• Malekshahi ZV, Gargari SLM, Rasooli I, Ebrahimizadeh W. 2011. Treatment of Helicobacter pylori infection in mice with oral administration of egg yolk-driven anti-UreC immunoglobulin. Microbial Pathogenesis. 51(5):366–372.
   PubMed Web of Science ®Google Scholar
• Mallapragada SK, Narasimhan B. 2008. Immunomodulatory biomaterials. Int J Pharm. 364(2):265–271.
   PubMedGoogle Scholar
• Mann JFS, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA. 2006. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods. 38(2):90–95.
   PubMed Web of Science ®Google Scholar
• Mannin MC, Chou DK, Murphy BM, Payne RW, Katayama DS. 2010. Stability of protein pharmaceuticals: an update. Pharm Res. 27:544–575.
   PubMed Web of Science ®Google Scholar
• Marasini N, Skwarczynski M, Toth I. 2014. Oral delivery of nanoparticle-based vaccines. Expert Rev Vaccines. 13(11):1361–1376.
   PubMed Web of Science ®Google Scholar
• Maurer JM, Hofman S, Schellekens RC, Tonnis WF, Dubois AO, Woerdenbag HJ, Hinrichs WL, Kosterink JG, Frijlink HW. 2016. Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: a feasibility study. Int J Pharm. 505(1–2):175–186.
   PubMedGoogle Scholar
• McConnell EL, Liu F, Basit AW. 2009. Colonic treatments and targets: issues and opportunities. J Drug Target. 17(5):335–363.
   PubMed Web of Science ®Google Scholar
• Mestecky J, Russell MW, Elson CO. 2007. Perspectives on mucosal vaccines: is mucosal tolerance a barrier? J Immunol. 179(9):5633–5638.
   PubMed Web of Science ®Google Scholar
• Meyer JD, Nayar R, Manning MC. 2009. Impact of bulking agents on the stability of a lyophilized monoclonal antibody. Eur J Pharm Sci. 38(1):29–38.
   PubMed Web of Science ®Google Scholar
• Montenegro-Nicolini M, Miranda V, Morales JO. 2017. Inkjet printing of proteins: an experimental approach. AAPS J. 19(1):234–243.
   PubMed Web of Science ®Google Scholar
• Morales JO, Brayden DJ. 2017. Buccal delivery of small molecules and biologics; of mucoadhsesive polymers, films and nanoparticles. Curr Opin in Pharm. 36:22–28.
   Google Scholar
• Morales JO, McConville JT. 2011. Manufacture and characterization of mucoadhesive buccal films. Eur J Pharma Biopharm. 77(2):187–199.
   PubMed Web of Science ®Google Scholar
• Morales JO, McConville JT. 2014. Novel strategies for the buccal delivery of macromolecules. Drug Dev Ind Pharm. 40(5):579–590.
   PubMed Web of Science ®Google Scholar
• Morein B, Simons K. 1985. Subunit vaccines against enveloped viruses: virosomes, micelles and other protein complexes. Vaccine. 3(2):83–93.
   PubMed Web of Science ®Google Scholar
• Morelli D, Ménard S, Colnaghi MI, Balsari A. 1996. Oral administration of anti-doxorubicin monoclonal antibody prevents chemotherapy-induced gastrointestinal toxicity in mice. Cancer Res. 56(9):2082–2085.
   PubMed Web of Science ®Google Scholar
• Moroz E, Matoori S, Leroux JC. 2016. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv Drug Deliv Rev. 1:108–121.
   Google Scholar
• Narasimhan B, Goodman JT, Vela JE. 2016. Rational design of targeted next-generation carriers for drug and vaccine delivery. Annu Rev Biomed Eng. 18:25–49.
   PubMed Web of Science ®Google Scholar
• Nayak B, Panda AK, Ray P, Ray AR. 2009. Formulation, characterization and evaluation of rotavirus encapsulated PLA and PLGA particles for oral vaccination. J Microencapsul. 26(2):154–165.
   PubMed Web of Science ®Google Scholar
• Nelson AL. 2010. Antibody fragments: hope and hype. mAbs. 2(1):77–83.
   PubMed Web of Science ®Google Scholar
• Odevall L, Hong D, Digilio L, Sahastrabuddhe S, Mogasale V, Baik Y, Choi S, Kim JH, Lynch J. 2018. The Euvichol story – development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships. Vaccine. 36(45):6606–6614.
   PubMed Web of Science ®Google Scholar
• Ogra P, Faden H, Welliver RC. 2001. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev. 14(2):430–445.
   PubMed Web of Science ®Google Scholar
• Ogra P, Okayasu H, Czerkinsky C, Sutter RW. 2011. Mucosal immunity to poliovirus. Expert Rev Vaccines. 10(10):1389–1392.
   PubMed Web of Science ®Google Scholar
• Ohtake S, Martin RA, Saxena A, Pham B, Chiueh G, Osorio M, Kopecko D, Xu D, Lechuga-Ballesteros D, Truong-Le V. 2011. Room temperature stabilization of oral, live attenuated Salmonella entericaserovarTyphi-vectored vaccines. Vaccine. 29(15):2761–2771.
   PubMed Web of Science ®Google Scholar
• Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD, Lechuga-Ballesteros D, Truong-Le V. 2010. Heat-stable measles vaccine produced by spray drying. Vaccine. 28(5):1275–1284.
   PubMed Web of Science ®Google Scholar
• Okayasu H, Sutter RW, Czerkinsky C, Ogra PL. 2011. Mucosal immunity and poliovirus vaccines: impact on wild poliovirusinfection and transmission. Vaccine. 29(46):8205–8214.
   PubMed Web of Science ®Google Scholar
• Palem CR, Dudhipala NR, Battu SK, Repka MA, Madhusudan RY. 2016. Development, optimization and in vivo characterization of domperidone-controlled release hot-melt-extruded films for buccal delivery. Drug Dev Ind Pharm. 42(3):473–484.
   PubMed Web of Science ®Google Scholar
• Pang Y, Zhang Y, Wang H, Jin J, Piao J, Piao J, Liu Q, Li W. 2013. Reduction of salmonella enteritidis number after infections by immunization of liposome-associated recombinant SefA. Avian Dis. 57(3):627–633.
   PubMed Web of Science ®Google Scholar
• Park KY, Chan Kwon I, Park KI. 2011. Oral protein delivery: current status and future prospect. React Funct Polym. 71:280–287.
   Web of Science ®Google Scholar
• Pastor M, Esquisabel A, Marquinez I, Talavera A, Pedraz JL. 2014. Cellulose acetate phthalate microparticles containing Vibrio cholera: steps toward an oral cholera vaccine. J Drug Target. 22(6):478–287.
   PubMed Web of Science ®Google Scholar
• Pavot V, Rochereau N, Genin C, Verrier B, Paul S. 2012. New insights in mucosal vaccine develpment. Vaccines. 30(2):142–154.
   PubMed Web of Science ®Google Scholar
• Pelaseyed T, Bergström JH, Gustafsson JK, Ermund A, Birchenough GMH, Schütte A, van der Post S, Svensson F, Rodríguez-Piñeiro AM, Nyström EEL, et al. 2014. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev. 260(1):8–20.
   PubMed Web of Science ®Google Scholar
• Petrovsy N, Aguilar JC. 2004. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 82:488–496.
   PubMed Web of Science ®Google Scholar
• Premanand B, Prabakaran M, Kiener TK, Kwang J. 2013. Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS One. 8(2):e55536.
   PubMed Web of Science ®Google Scholar
• Ratanji KD, Derrick JP, Dearman RJ, Kimber I. 2014. Immunogenicity of therapeutic proteins: influence of aggregation. J Immunotoxicol. 11(2):99–109.
   PubMed Web of Science ®Google Scholar
• Razinkov VI, Treuheit MJ, Becker GW. 2015. Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools. J Biomol Screen. 20(4):468–483.
   PubMedGoogle Scholar
• Reilly RM, Domingo R, Sandhu J. 1997. Oral delivery of antibodies: future. Pharmacokinetic Trends. 32(4):313–323.
   PubMed Web of Science ®Google Scholar
• Renukuntla J, Vadlapudi AD, Patel A, Boddu SHS, Mitra AK. 2013. Approches for enhancing oral bioavailability of peptides and proteins. Int J Pharma. 447(1–2):75–93.
   PubMed Web of Science ®Google Scholar
• Resch TK, Wang Y, Moon SS, Joyce J, Li S, Prausnitz M, Jiang B. 2018. Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice. Sci Rep. 8(1):561.
   PubMedGoogle Scholar
• Rexroad J, Wiethoff CM, Jones LS, Middaugh CR. 2002. Lyophilization and the thermostability of vaccines. Cell PreservTechnol. 1:91–104.
   Google Scholar
• Roblegg E, Fröhlich E, Meindl C, Teubl B, Zaversky M, Zimmer A. 2012. Evaluation of a physiological in vitro system to study the transport of nanoparticles through the buccal mucosa. Nanotoxicology. 6:399–413.
   PubMed Web of Science ®Google Scholar
• Salman HH, Irache JM, Gamazo C. 2009. Immunoadjuvant capacity of flagellin and mannosamine-coated poly (anhydride) nanoparticles in oral vaccination. Vaccine. 27(35):4784–4790.
   PubMed Web of Science ®Google Scholar
• Sander MT, Brown LE, Deliyannis G, Pearse MJ. 2005. ISCOMTM‐based vaccines: the second decade. Immunol Cell Biol. 83:119–128.
   PubMed Web of Science ®Google Scholar
• Sarciau JM, Hageman MJ. 1997. Effects of bovine somatotropin (rbSt) concentration at different moisture levels on the physical stability of sucrose in freeze-dried rbSt/sucrose mixtures. J Pharm Sci. 86:365–371.
   PubMed Web of Science ®Google Scholar
• Sasaki N, Yamashita T, Takeda M, Shinohara M, Nakajima K, Tawa H, Usui T, Hirata K. 2009. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation. 120(20):1996–2005.
   PubMed Web of Science ®Google Scholar
• Schwenener RA. 2014. Liposomes as vaccine delivery systems: a review of the recent advances. Vaccines. 2:159–182.
   Google Scholar
• Scott AM, Wolchok JD, Old LJ. 2012. Antibody therapy of cancer. Nat Rev Cancer. 12(4):278–287.
   PubMed Web of Science ®Google Scholar
• Shukla A, Katare OP, Singh B, Vyas SP. 2010. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm. 385(1–2):47–52.
   PubMed Web of Science ®Google Scholar
• Shukla A, Mishra V, Kesharwani P. 2016. Bilosomes in the context of oral immunization: development, challenges and opportunities. Drug Disc Today. 21(6):888–899.
   PubMed Web of Science ®Google Scholar
• Singh A, Peppas NA. 2014. Hydrogels and scaffolds for immunomodulation. Adv Mater. 26(38):6530–6541.
   PubMed Web of Science ®Google Scholar
• Singh BN. 2007. Modified-release solid formulations for colonic delivery. Recent Pat Drug Deliv Formul. 1(1):53–63.
   PubMedGoogle Scholar
• Singh M, Kazzaz J, Ugozzoli M, Malyala P, Chesko J, O’Hagan D. 2006. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv. 3(1):115–120.
   PubMedGoogle Scholar
• Sliwkosi MX, Mellman I. 2013. Antibody therapeutics in cancer. Science. 341:1192–1198.
   PubMed Web of Science ®Google Scholar
• Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, de Beer MC, Van der Merwe CF, Delem A. 2010. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 28(39):6542–6548.
   PubMed Web of Science ®Google Scholar
• Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, et al. 2011. Efficacy of a low-cost inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis. 5(10):e1289.
   PubMed Web of Science ®Google Scholar
• Taddio A, Ipp M, Thivakaran S, Jamal A, Parikh C, Smart S, Sovran J, Stephens D, Katz J. 2012. Survey of the prevalence of immunization non-compliance due to needle fears in children and adults. Vaccine. 30(32):4807–4812.
   PubMed Web of Science ®Google Scholar
• Tajarobi F, Abrahmsén-Alami S, Hansen M, Larsson A. 2009. The impact of dose and solubility of additives on the release from HPMC matrix tablets—identifying critical conditions. Pharm Res. 6:1496–1503.
   Google Scholar
• Talavera A, Año G, Pino Y, Castaño J, Uribarri E, Riverón L, Gil S, Fernández S, Cedré B, Valmaseda T. 2006. Formulation in tablets of a cholera whole cells inactivated vaccine candidate. Vaccine. 24(16):3381–3387.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Ertl H. 2004. Adenoviruses as vaccine vectors. Mol Ther. 10(4):616–629.
   PubMed Web of Science ®Google Scholar
• Tawde SA, Chablani L, Akalkotkar A, D’Souza MJ. 2016. Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery. J Control Release. 235:147–154.
   PubMed Web of Science ®Google Scholar
• Teubl BJ, Meindl C, Eitzlmayr A, Zimmer A, Fröhlich E, Roblegg E. 2013. In‐vitro permeability of neutral polystyrene particles via buccal mucosa. Small. 9:457–466.
   PubMed Web of Science ®Google Scholar
• Tonnis WF, Mensink MA, de Jager A, Van der Voort Maarschalk K, Frijlink HW, Hinrichs WL. 2015. Size and molecular flexibility of sugars determine the storage stability of freeze-dried proteins. Mol Pharm. 12(3):684–694.
   PubMed Web of Science ®Google Scholar
• Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A. 2002. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. Bulletin World Health Organ. 80:2–8.
   PubMed Web of Science ®Google Scholar
• Van de Weert M, Hennink WE, Jiskoot W. 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res. 17(10):1159–1167.
   PubMed Web of Science ®Google Scholar
• Vehring R, Ao Y, inventors; MEDIMMUNE, LLC, assignee. 2010 Nov 25. Preservation of bioactive materials by freeze-dried foam. Patent Application Publication, United States patent US2010/0297231 A1.
   Google Scholar
• Viswanathan P, Muralidaran Y, Ragavan G. 2017. Nanostructures for oral medicine. Micro and Nano Technologies. Amsterdam, Netherlands: Elsevier. Chapter 7, Challenges in oral drug delivery: a nano-based strategy to overcome; p. 173–201.
   Google Scholar
• Walker RI. 2005. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine. 23(26):3369–3385.
   PubMed Web of Science ®Google Scholar
• Walters RH, Bhatnagar B, Tchessalov S, Izutsu K, Tsumoto K, Ohtake S. 2014. Next generation drying technologies for pharmaceutical applications. J Pharm Sci. 103(9):2673–2695.
   PubMed Web of Science ®Google Scholar
• Wambura PN. 2011. Formulation of novel nano-encapsulated Newcastle disease vaccine tablets for vaccination of village chickens. Trop Anim Health Prod. 43(1):165–169.
   PubMed Web of Science ®Google Scholar
• Wang B, Tchessalov S, Warne NW, Pikal MJ. 2009. Impact of sucrose level on storage stability of proteins in freeze-dried solids: I. Correlation of protein-sugar interaction with native structure preservation. J Pharm Sci. 98(9):3131–3144.
   PubMed Web of Science ®Google Scholar
• Wang N, Wang T, Zhang M, Chen R, Niu R, Deng Y. 2014. Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant delivery system. Eur J Pharm Biopharm. 88(1):194–206.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu H, Zhang X, Qian F. 2015. Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein Cell. 6(7):480–503.
   PubMed Web of Science ®Google Scholar
• Wang T, Zhen Y, Ma X, Wei B, Li S, Wang N. 2015. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain. Colloids Surf B Biointerfaces. 126:520–530.
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci. 96(1):1–26.
   PubMed Web of Science ®Google Scholar
• Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 289(1–2):1–30.
   PubMed Web of Science ®Google Scholar
• Wilkhu JS, McNeil SE, Anderson DE, Kirchmeier M, Perrie Y. 2017. Development of a solid dosage platform for the oral delivery of bilayervesicles. Eur J Pharm Sci. 108:71–77.
   PubMed Web of Science ®Google Scholar
• Wilkhu JS, McNeil SE, Anderson DE, Perrie Y. 2014. Consideration of the efficacy of non-ionic vesicles in the targeted delivery of oral vaccines. Drug Deliv and Transl Res. 4:233–245.
   PubMed Web of Science ®Google Scholar
• Willrich MA, Murray DL, Snyder MR. 2015. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 165(2):270–282.
   PubMed Web of Science ®Google Scholar
• Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. 2009. Vaccine adjuvants: current challenges and future approaches. J Pharm Sci. 98(4):1278–1316.
   PubMed Web of Science ®Google Scholar
• Worledge KL, Godiska R, Barrett TA, Kink JA. 2000. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats. Dig Dis Sci. 45(12):2298–2305.
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, Kirkland R, Deshpande AR, Singh S, Abreu MT. 2016. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study. Gut. 65(2):249–255.
   PubMed Web of Science ®Google Scholar
• Yeh TH, Hsu LW, Tseng MT, Lee PL, Sonjae K, Ho YC, Sung HW. 2011. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials. 32(26):6164–6173.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhao Q, Zhang Y, Han N, Hu L, Zhang C, Jiang T, Wang S. 2014. Investigation of 3-D ordered materials with a high adsorption capacity for BSA and their potential application as an oral vaccine adjuvant. J Colloid Interface Sci. 434:113–121.
   PubMed Web of Science ®Google Scholar
• Zheng JY, Janis LJ. 2006. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int J Pharm. 308(1–2):46–51.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Talton J, Zhang G, Cunningham T, Wang Z, Waters RC, Kirk J, Eppler B, Dennis MK, Sui Y, et al. 2012. Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med. 18(8):1291–1296.
   PubMed Web of Science ®Google Scholar